Blue Wolf Capital Partners, a US-based private equity firm, has agreed to acquire seven Recipharm sites from EQT Private Equity, subject to regulatory approval in a deal that should close in Q4. These are located at Solna, Strängnäs, Höganäs, Karlskoga and Uppsala in Sweden; Pessac, France; and Parets, Spain.
Jubilant Ingrevia has commissioned a new 2,000 tonnes/year facility for diketene derivatives at Gajraula in India’s Uttar Pradesh state. The company’s supplies these to the pharmaceuticals, agrochemicals and other industries, including the US and the EU. This and early efforts to get customer product approvals, are expected to account for much of the capacity utilisation in the coming months.
EuroAPI has suspended all API production at its site in Brindisi, Italy, until further notice. This followed an internal audit in which “quality control deficiencies due to potential local misconduct” were identified. These are being further investigated.
W.R. Grace has formally opened an expansion of the pharmaceutical CDMO expansion project it began 21 months ago at its site in South Haven, Michigan. The expansion has added 25% more capacity, including a new 15 m3 Hastelloy centrifuge and three 15 m3 multi-purpose chemical reactors.
Almac Group has announced the completion of two new purpose-built facilities at its headquarters in Craigavon, Northern Ireland. The total investment is about $400 million and is part of a global investment programme announced in June 2022.
One is a 2,600 m2 GMP facility that more than doubles peptide API manufacturing capacity. This “will enhance synthesis, purification and isolation capabilities and meet anticipated demand for clinical development and commercial products”, the company said.
Noramco, an API supplier specialised in controlled substances, has launched Noramco Group, which it describes as a “comprehensive North American-based supply chain solution” for clinical and commercial APIs and drug products. Noramco Group unites the capabilities of three subsidiaries:
* Delaware-based Noramco itself, which supplies APIs for both branded and generic drugs that are used in over 350 products
* Purisys, a Georgia-based supplier of CDMO services and pharmaceutical reference standards, with specialised capabilities in controlled substance APIs
CordenPharma has announced the commissioning of new GMP capacities at its Frankfurt site to manufacture early clinical phase peptide APIs. The investment is still being finalised, but will be fully operational in Q2 and authorised by German authorities in 2H.
